Skip to main content
. 2021 Oct 18;2:751798. doi: 10.3389/fresc.2021.751798

Table 1.

Comorbid conditions associated with chronic cough in patients with IPF.

System Diagnosis Proposed mechanisms of cough Prevalence in IPF
Respiratory and sleep Infection: tuberculosis, pertussis, lung abscess, protracted bacterial bronchitis Excess mucous production, loss of ciliary structure, airway inflammation NA*
Chronic obstructive pulmonary disease, bronchiectasis Excess mucous production, C-fiber nerve activity 6–67% (37)
Asthma Bronchial hyperreactivity 8.5–18.6% (38)
Lung cancer C-fiber nerve activity 10–30% (39)
Obstructive sleep apnoea Upper airway inflammation and injury due to airway obstruction 22–90% (40)
Ear nose and throat Earwax or foreign body Stimulation of branch of the vagal nerve innervating external auditory canal NA
Chronic sinusitis Direct irritation of the vocal cords, sensitization of the cough reflex NA
Vocal cord dysfunction Paradoxical vocal cord movement and glottis closure with airway narrowing NA
Gastrointestinal Gastro-esophageal reflux disease Microaspiration and direct irritation, sensitization of the cough reflex due to activation of vagal nerve endings in the esophagus 87–94% (4144)
Cardiovascular Left ventricular failure Pulmonary c-fibers activated by pulmonary venous congestion and oedema (45) 4–26% (37)
Arrhythmia Mediators of cough (bradykinin and substance P) accumulate in the upper airway NA§
Drugs/toxins Angiotensin-converting enzyme inhibitor use Mediators of cough (bradykinin and substance P) accumulate in the upper airway NA

IPF, idiopathic pulmonary fibrosis; NA, not available; TB, tuberculosis.

*

Incidence of TB 6.3% (46) in an observational study of 143 patients in South Korea.

Asthma diagnosed in the year prior to IPF diagnosis.

GOR measured by ambulatory pH monitoring rather than impedance.

§

In a retrospective study of patients who underwent lung transplantation for IPF, the incidence of atrial arrhythmia was 25.4% in 366 patients (47).

Note in the ASCEND (48) and CAPACITY (49) studies 111 of 624 patients with IPF were on an Angiotensin-converting enzyme (ACE) inhibitor at randomization (50).